PTEN and neoplasm: First, the P3K/AKT pathway is activated in approximately 25% of TNBC, which includes the loss of PTEN tumor suppressor, which was, in preclinical tumor models, associated with inhibition of antitumor activity of T cells and resistance to anti-PD-1 therapy [173].